Stockscreener 앱 받기
153.89
0.18%
-0.47
전일 마감가:
$154.36
열려 있는:
$154.8
하루 거래량:
501.31K
Relative Volume:
0.44
시가총액:
$15.46B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
32.97
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
-4.49%
1개월 성능:
+17.09%
6개월 성능:
+10.86%
1년 성능:
+25.31%
1일 변동 폭
$153.71
$156.48
1주일 범위
$153.27
$162.39
52주 변동 폭
$117.59
$162.39
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
153.77 | 15.81B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.71 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.295 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.37 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.22 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
564.23 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Morgan Stanley lists Rule 144 sale of NBIX-linked shares | NBIX SEC FilingForm 144 - Stock Titan
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock By Investing.com - Investing.com Australia
Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com UK
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules - Tehachapi News
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - ChartMill
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - Yahoo Finance
Neurocrine Biosciences (NBIX) Stock Analysis: Strong Buy Ratings and 20% Upside Potential - DirectorsTalk Interviews
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien - AD HOC NEWS
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences director Norwalk sells $590,601 in stock - Investing.com
Neurocrine Biosciences director Norwalk sells $590,601 in stock By Investing.com - Investing.com Canada
Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan - Stock Titan
Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position - AD HOC NEWS
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine Biosciences stock hits all-time high at 160.31 USD By Investing.com - Investing.com Nigeria
A Look at Neurocrine Biosciences Inc (NBIX) After 3.5% Gain -- G - GuruFocus
Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates - simplywall.st
Number of shareholders of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView
Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity - ChartMill
Neurocrine stock soars 61% after InvestingPro Fair Value signal By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| POPS RICHARD F | Director |
May 15 '26 |
Option Exercise |
47.89 |
15,000 |
718,350 |
49,480 |
| POPS RICHARD F | Director |
May 15 '26 |
Sale |
157.65 |
15,000 |
2,364,760 |
34,480 |
3.04%
자본화:
|
볼륨(24시간):